Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

OptimizeRx (OPRX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to 0.72.

  • OptimizeRx's Equity Ratio rose 360.04% to 0.72 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.72, marking a year-over-year increase of 360.04%. This contributed to the annual value of 0.68 for FY2024, which is 95.76% down from last year.
  • Per OptimizeRx's latest filing, its Equity Ratio stood at 0.72 for Q3 2025, which was up 360.04% from 0.7 recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Equity Ratio ranged from a high of 0.96 in Q1 2021 and a low of 0.68 during Q4 2024
  • Moreover, its 5-year median value for Equity Ratio was 0.94 (2022), whereas its average is 0.84.
  • As far as peak fluctuations go, OptimizeRx's Equity Ratio skyrocketed by 2311.03% in 2021, and later plummeted by 2666.81% in 2024.
  • OptimizeRx's Equity Ratio (Quarter) stood at 0.93 in 2021, then grew by 0.51% to 0.94 in 2022, then decreased by 26.31% to 0.69 in 2023, then fell by 0.96% to 0.68 in 2024, then rose by 5.02% to 0.72 in 2025.
  • Its last three reported values are 0.72 in Q3 2025, 0.7 for Q2 2025, and 0.69 during Q1 2025.